VITAE PHARMACEUTICALS LLC has a total of 63 patent applications. It increased the IP activity by 41.0%. Its first patent ever was published in 2014. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and machines are FUJI YAKUHIN CO LTD, BOMBRUN AGNES and AMAKEM NV.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 15 | |
#2 | Australia | 9 | |
#3 | EPO (European Patent Office) | 9 | |
#4 | Israel | 7 | |
#5 | Republic of Korea | 3 | |
#6 | Brazil | 2 | |
#7 | Canada | 2 | |
#8 | Chile | 2 | |
#9 | Colombia | 2 | |
#10 | Hungary | 2 | |
#11 | Mexico | 2 | |
#12 | Philippines | 2 | |
#13 | Singapore | 2 | |
#14 | Hong Kong | 1 | |
#15 | Serbia | 1 | |
#16 | Taiwan | 1 | |
#17 | Ukraine | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Machines |
# | Name | Total Patents |
---|---|---|
#1 | Zhuang Linghang | 36 |
#2 | Fan Yi | 36 |
#3 | Singh Suresh B | 34 |
#4 | Claremon David A | 32 |
#5 | Lotesta Stephen D | 30 |
#6 | Dillard Lawrence Wayne | 28 |
#7 | Dong Chengguo | 27 |
#8 | Zheng Yajun | 26 |
#9 | Yuan Jing | 26 |
#10 | Jia Lanqi | 25 |
Publication | Filing date | Title |
---|---|---|
US2020148677A1 | Inhibitors of RORγ | |
AU2017326006A1 | Inhibitors of the menin-MLL interaction | |
US2018222860A1 | Substituted indoles as modulators of ROR-gamma |